Mirum

Mereo BioPharma

The company develops clinical-stage therapies for patients with rare diseases, including osteogenesis imperfecta and alpha-1 antitrypsin deficiency-associated lung disease.

Northsea Therapeutics

This company develops structurally engineered fatty acid drugs for patients with metabolic, inflammatory, and fibrotic diseases such as rare liver disorders.

Ultragenyx

This biopharmaceutical company develops and commercialises therapies for patients with serious rare and ultra-rare genetic diseases.

Cymabay Therapeutics

This biopharmaceutical company develops oral therapies for patients with chronic liver diseases and metabolic disorders including primary biliary cholangitis.

Calliditas therapeutics

This biopharmaceutical company develops and commercialises medicines for patients with rare renal and hepatic diseases.

Intercept Pharmaceuticals

This company develops and commercialises small molecule therapeutics to treat chronic liver diseases for healthcare providers and patients.

MRM Health

This biopharmaceutical company develops microbiome-based live biotherapeutic products for patients with chronic inflammatory diseases and immune-oncology conditions.

Abliva

This biopharmaceutical company develops novel medicines for patients suffering from rare and severe primary mitochondrial diseases.